University College London Hospitals NHS
NHS Foundation Trust

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
December 2017

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (known as Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below, a summary of performance submitted by UCLH in Quarter 3 (2017/18) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of December 2017.

For Further information on PID reporting, please visit the NIHR pages at:
http://www.nihr.ac.uk/policy-and-standards/Performance-in-initiating-and-delivering-research.htm

Initiating Clinical Research – HRA Approval

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Date of First Patient Recruited	Benchmark Met	Reasons for delay correspond to:
1	16/LO/1677	191232	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWIN2	27/10/2016	16/01/2017			18/04/2017		18/04/2017	16/05/2017	No	Sponsor
2	16/LO/1776	191954	TIPS microspheres for perianal fistula		18/01/2017	17/01/2017	17/02/2017		17/02/2017		06/06/2017	No	Sponsor
3	16/SC/0590	191279	Depletion of Serum Amyloid P Component in Alzheimer's Disease (DESPIAD)	12/12/2016	02/03/2017	16/02/2017	09/05/2017		25/05/2017			No	Sponsor
4	16/LO/1999	200065	A comparison of CBTi and usual treatment for tinnitus related insomnia		17/01/2017	09/02/2017	24/02/2017		24/02/2017		26/06/2017	no	Sponsor

5	17/LO/1055	228923	Elective rituximab in TTP	06/06/2017	10/08/2017	01/08/2017	31/08/2017		01/09/2017		13/10/2017	Yes	
6	17/NE/0058	219540	GARNET	24/02/2017	27/02/2017	13/04/2017	14/06/2017		14/06/2017		26/06/2017	No	Sponsor
7	17/NW/0330	222996	Agios AG120-C-005	26/07/2016	12/06/2017			02/11/2017		03/11/2017		No	Sponsor
8	17/LO/0038	182633	UKP3BEP Trial	08/03/2017	13/12/2017							Within 70 days	
9	16/LO/1755	209250	REVITA-2		31/01/2017	24/01/2017	01/03/2017		02/03/2017		28/04/2017	No	Neither
10	17/EM/0217	200797	ICEMAN		06/09/2017			12/09/2017		12/09/2017	24/11/2017	No	Sponsor
11	17/LO/1861	210692	NEOlung	15/08/2016	06/12/2017							Within 70 days	
12	17/YH/0050	207335	MBSR in adolescents with	16/02/2017	24/03/2017	02/03/2017	11/04/2017		12/04/2017		25/04/2017	Yes	

			IBD										
13	16/YH/0157	204585	PersonaLising Anal cancer radioTherapy dOse - PLATO	05/05/2017	18/09/2017							No	Neither
14	17/YH/0076	208944	CALM-DIEM	25/08/2016	19/06/2017	18/05/2017	22/06/2017		21/07/2017			No	Sponsor
15	17/LO/0024	212247	Eli Lilly JPCJ	30/08/2016	03/10/2017			03/10/2017		03/10/2017	31/10/2017	Yes	
16	17/LO/0117	217367	ALLCAR19	09/08/2017	23/08/2017			25/09/2017		28/09/2017	01/10/2017	Yes	
17	16/LO/1004	207544	MIROCALS	06/09/2016	20/02/2017			19/06/2017		22/06/2017	26/09/2017	No	Sponsor
18	16/SS/0014	187949	GEM-3	12/09/2016	14/11/2017	14/10/2016						Within 70 days	
19	17/LO/0001	211800	DTX-301	13/09/2016	16/02/2017			23/08/2017		23/08/2017		No	Sponsor

20	16/NE/0370	214375	SIDEROS		06/01/2017	29/12/2016	14/03/2017		20/03/2017		15/06/2017	No	Sponsor
21	16/NE/0418	211187	iROC	23/09/2016	25/01/2017	25/01/2017	17/02/2017		17/02/2017		21/03/2017	Yes	
22	16/SC/0376	202786	TRoMbone		27/02/2017	10/10/2016	10/03/2017		13/03/2017		19/05/2017	No	Neither
23	17/SC/0369	218189	NEPTUNES	24/05/2017	17/10/2017	06/10/2017	31/10/2017		30/11/2017			No	Sponsor
24	17/EE/0016	206408	A Randomised Control Trial of SEEG Electrode Placement methods	16/08/2017	25/09/2017			06/10/2017		06/10/2017	01/11/2017	Yes	
25	17/LO/0736	225746	BMS CN002012 (0078-1422)	27/09/2016	22/05/2017			12/10/2017		12/10/2017	01/11/2017	No	Sponsor
26	16/LO/2157	217001	An efficacy, safety and tolerability study of Fosmetpantotenate in PKAN	29/09/2016	10/07/2017	13/07/2017	23/10/2017		20/12/2017			No	Sponsor

27	17/SC/0033	218114	Combination therapy with isatuximab in patients with multiple myeloma	11/10/2016	19/01/2017	29/03/2017	13/04/2017		13/04/2017		30/05/2017	No	Sponsor
28	17/LO/0475	220177	CABRIO proof of concept study V1.1 020217		12/04/2017	12/04/2017	18/05/2017		25/05/2017		24/08/2017	No	Sponsor
29	17/EM/0063	213979	Astellas APGD 2215-CL-0302	13/10/2016	15/03/2017	27/04/2017	23/05/2017		02/06/2017			No	Sponsor
30	17/NE/0165	217768	MA30143	13/10/2016	09/08/2017			02/11/2017		06/11/2017	15/12/2017	No	Sponsor
31	17/LO/0640	204303	Efficacy & Safety of UX007 in Movement Disorders associated to Glut1DS	20/10/2016	04/04/2017	04/08/2017	25/08/2017		11/09/2017		28/11/2017	No	Sponsor
32	16/EE/0357	206501	Opicapone in clinical practice (OPTIPARK)	24/10/2016	09/08/2017	31/10/2016		05/12/2017				Site not confirmed	Sponsor
33	17/LO/0247	213278	A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949	26/10/2016	14/02/2017	24/05/2017	23/08/2017		24/08/2017		18/09/2017	No	Sponsor

34	17/WM/0105	214955	GSK525762	27/10/2016	08/03/2017			31/05/2017		01/06/2017		No	Sponsor
35	16/LO/1960	199019	Dose finding study of Sarilumab in children with sJIA	07/11/2016	07/03/2017	28/02/2017	07/03/2017		20/04/2017			No	Neither
36	16/NE/0183	197040	TOPSAT2	08/11/2016	31/01/2017	13/07/2016	25/04/2017		27/04/2017			No	Sponsor
37	17/SC/0185	214076	BGB-3111-302	10/11/2016	25/04/2017			28/07/2017		08/08/2017	22/08/2017	No	Sponsor
38	17/LO/0169	214075	Effect of MD1003 in progressive MS: a randomized double blind placebo controlled study	14/11/2016	13/02/2017	21/04/2017	09/05/2017		26/05/2017		21/06/2017	No	Neither
39	17/EE/0205	224373	GMI-1271	16/11/2016	15/03/2017			18/10/2017		20/10/2017		No	Neither
40	17/EM/0152	216307	Astellas 2215-CL-0304	17/11/2016	24/05/2017			29/09/2017		29/09/2017		No	Sponsor

41	16/EM/0324	204032	Safety & Efficacy of suvorexant for treatment of insomnia in AD subjects	20/07/2017	25/09/2017			24/11/2017		24/11/2017	17/01/2018	No	Sponsor
42	17/LO/0011	217376	VEROnA	22/11/2016	19/01/2017	15/02/2017	08/05/2017		09/05/2017		11/08/2017	No	Sponsor
43	16/LO/2150	201093	OCTOVA	25/11/2016	27/01/2017			12/05/2017		12/05/2017	25/07/2017	No	Sponsor
44	16/LO/2186	188540	Randomised phase I/II study of Intensity Modulated Arc Therapy techniques in abdominal neuroblastoma		17/01/2017	17/01/2017	21/02/2017		21/02/2017		01/03/2017	Yes	
45	17/LO/0285	211245	G1T38-02_Phase 1/2 Safety & PK Study of G1T38_Breast Cancer_3652/0002	05/12/2016	24/02/2017	05/04/2017	15/05/2017		25/05/2017			No	Sponsor
46	17/SC/0276	220437	MAKO medial unicompartmental knee arthroplasty	17/07/2017	08/08/2017	01/08/2017	15/08/2017		15/08/2017		24/11/2017	No	Sponsor

47	17/EM/0032	209811	RECLAIM: Reclassifying constipation using MRI and high resolution manometry	09/12/2016	07/03/2017			20/04/2017		26/04/2017		No	Sponsor
48	17/LO/0769	218626	Structured education group versus audio-visual information in IBS	12/05/2017	25/05/2017	12/05/2017	02/06/2017		02/06/2017		20/06/2017	Yes	
49	17/LO/0741	216587	MOVES-PD	19/12/2016	24/05/2017			06/11/2017		07/12/2017		No	Sponsor
50	16/LO/0986	202286	CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 577	21/12/2016	16/02/2017	10/08/2016	05/04/2017		12/04/2017			No	Neither
51	16/NE/0279	198051	TIDaL	04/01/2017	24/03/2017			11/04/2017		11/04/2017	16/05/2017	Yes	

52	16/EE/0463	214371	CLEE011A2404. Ribociclib and Letrozole in HR+, HER- breast cancer		16/03/2017			16/03/2017		16/03/2017	06/04/2017	Yes	
53	17/LO/0627	218496	VAL-1221	09/01/2017	01/06/2017	19/06/2017	03/10/2017		04/10/2017		08/11/2017	No	Sponsor
54	17/LO/0048	216896	Adaptimmune ADP-0022-003	12/01/2017	31/03/2017	26/04/2017	16/10/2017		23/10/2017			No	Sponsor
55	16/WM/0512	218042	AEGIS Kids PK (ST10-01-103)	12/01/2017	24/01/2017			18/07/2017		27/07/2017		No	Sponsor
56	16/LO/1502	178292	CTC-STOP	16/01/2017	16/01/2017	07/10/2016	02/05/2017		27/04/2017			No	Sponsor
57	17/NE/0115	218417	MA39189 Trial Of Pirfenidone in Patients with Fibrosing uILD	16/01/2017	17/04/2017	26/05/2017	23/06/2017		14/07/2017		03/01/2018	No	Neither
58	16/LO/2148	219354	Intraprostatic PRX302 injection to treat localised prostate cancer /2b	23/01/2017	24/01/2017			28/07/2017		31/07/2017	14/09/2017	No	Sponsor

59	16/LO/2141	200571	Biomede	26/01/2017	03/03/2017	06/04/2017	17/05/2017		29/06/2017		07/07/2017	No	Sponsor
60	17/WM/0106	201079	MRI for early response prediction to anti-TNF therapy	27/01/2017	08/05/2017	28/04/2017	02/06/2017		13/06/2017		30/08/2017	No	Sponsor
61	16/WS/0197	186191	ATLANTIS	03/02/2017	16/02/2017			18/05/2017		02/06/2017	20/09/2017	No	Sponsor
62	17/LO/0893	211137	Hu5F9-G4 (47NHL)	03/02/2017	29/06/2017							No	Sponsor
63	17/EE/0128	222308	GEN-GCT	06/02/2017	24/04/2017	19/05/2017	07/08/2017		09/08/2017			No	Sponsor
64	17/EE/0384	218262	RCT of Apatinib in Patients with Advanced or Metastatic Gastric Cancer (GC)	07/02/2017	04/09/2017				31/10/2017			Site not confirmed	Sponsor
65	17/LO/0948	222446	FABULAS	02/11/2017	13/11/2017					28/12/2017		Within 70 days	

66	17/LO/1019	223213	AFPc332T in Advanced HCC	09/02/2017	01/08/2017	15/09/2017						No	Neither
67	17/LO/0852	223047	Cryoablation (8 seconds) for the Management of Barrett's Oesophagus	10/10/2017	20/10/2017	10/10/2017	25/10/2017		10/11/2017		17/11/2017	Yes	
68	16/LO/1810	209789	A Phase 3 - Ublituximab in Combination with TGR-1202	10/02/2017	02/03/2017	03/01/2017	09/06/2017		16/06/2017			No	Sponsor
69	17/NW/0168	218752	CA209-744	10/02/2017	17/07/2017	01/06/2017	09/08/2017		11/08/2017		12/10/2017	No	Neither
70	17/LO/1043	226184	INCB24360:epacadostat in combination with pembrolizumab and azacitadine	14/02/2017	06/10/2017			25/10/2017		30/10/2017	21/11/2017	Yes	
71	17/WM/0017	201600	(MifeMiso trial)	16/02/2017	11/04/2017	06/04/2017	27/06/2017		06/07/2017		13/10/2017	No	Sponsor
72	17/EM/0183	220783	Effect of Mepolizumab in severe bilateral nasal polyps	27/02/2017	11/05/2017			16/08/2017		23/08/2017	13/11/2017	No	Sponsor

73	17/LO/0797	220423	ABRE Study	28/02/2017	08/08/2017	01/08/2017	16/11/2017		30/11/2017			No	Sponsor
74	16/WM/0501	185601	Wisteria	28/02/2017	01/03/2017	28/02/2017	11/09/2017		20/09/2017			No	Sponsor
75	17/LO/0959	223644	LITTLE JOURNEY TRIAL	30/06/2017	01/07/2017	30/06/2017	06/07/2017		06/07/2017		14/07/2017	Yes	
76	17/LO/1458	204582	ASD-Probiotic V.3	22/08/2017	09/11/2017			17/11/2017		17/11/2017		Within 70 days	
77	17/NW/0175	222859	Phase 1b Open-Label, Dose Escalation Study of PRTX-100	07/03/2017	06/03/2017			23/05/2017		27/06/2017	27/09/2017	No	Neither
78	17/LO/0372	220433	REACH 2	10/03/2017	15/03/2017			17/05/2017		20/07/2017	11/08/2017	No	NHS provider
79	16/LO/1495	207629	SPACE	15/03/2017	16/06/2017			27/07/2017		04/08/2017	05/10/2017	No	Sponsor

80	16/SC/0657	182046	ACCEPT	20/03/2017	22/03/2017	28/02/2017	23/05/2017		23/05/2017		24/07/2017	No	Sponsor
81	17/LO/0284	221453	Single doses of GSK3008348 in IPF patients using PET imaging	21/03/2017	15/02/2017			11/05/2017		12/05/2017	13/06/2017	No	Sponsor
82	17/LO/0494	224195	Bluebirdbio HGB-212	28/03/2017	08/06/2017	24/05/2017	28/06/2017		30/06/2017		02/08/2017	Yes	
83	17/NW/0317	224142	Krio	30/03/2017	02/06/2017			14/08/2017		30/08/2017		No	Neither
84	17/LO/0427	199962	N3	05/04/2017	30/06/2017							No	Sponsor
85	17/LO/0812	226255	Treatment with CD19/CD22 CAR redirected T cells for DLBCL-ALEXANDER	10/04/2017	06/07/2017			25/08/2017		05/09/2017	07/09/2017	Yes	

86	17/NW/0228	222219	Phase 3 Carfilzomib Study in Patients With Relapsed/Refractory Myeloma	18/04/2017	08/06/2017			11/10/2017		11/10/2017	15/11/2017	No	Sponsor
87	17/YH/0181	227102	TAK-659 for DLBCL patients after 2 prior lines of chemotherapy	21/04/2017	30/05/2017			25/08/2017		13/09/2017	25/09/2017	No	Sponsor
88	17/EM/0155	206803	POINT	05/05/2017	15/05/2017			01/12/2017		05/12/2017		No	Neither
89	16/WM/0472	211270	CONFIRM	26/04/2017	05/05/2017	14/03/2017	07/06/2017		01/08/2017			No	Neither
90	17/NW/0193	216411	IntAct	26/04/2017	12/12/2017			18/12/2017				Within 70 days	
91	17/LO/0440	217506	A Phase 1 Study to Evaluate ISIS 814907 in Mild Alzheimer's Disease	26/04/2017	26/04/2017	20/06/2017	21/07/2017		25/07/2017		23/08/2017	No	Sponsor

92	17/EM/0166	222665	AVAIL-T	05/05/2017	04/08/2017			07/08/2017		16/08/2017	27/11/2017	No	Neither
93	17/SC/0055	219468	Secukinumab treatment in Juvenile Idiopathic Arthritis	09/05/2017	16/05/2017	27/03/2017	25/09/2017		28/09/2017			No	Sponsor
94	17/LO/1060	187783	SUBSoNIC	10/08/2017	15/08/2017			14/11/2017		23/11/2017		No	Sponsor
95	17/NW/0312	211974	EORTC protocol 1317-STBSG	10/05/2017	09/06/2017			07/08/2017		09/08/2017	23/10/2017	No	Sponsor
96	17/EE/0264	228153	POSEIDON	11/05/2017	16/06/2017			12/09/2017		18/09/2017		No	Sponsor
97	16/EE/0546	210292	BEST3	16/05/2017	19/05/2017			24/08/2017				No	Sponsor

98	17/LO/1367	225049	MO29872: Atezolizumab compared with chemotherapy in NSCLC	25/05/2017	01/11/2017			02/11/2017		08/12/2017		Within 70 days	
99	17/ES/0051	223060	NuCana PRO-105	08/06/2017	07/08/2017			28/09/2017		28/09/2017	26/10/2017	No	Sponsor
100	16/SC/0584	198941	SINAPPS2	12/06/2017	12/06/2017			31/08/2017		25/09/2017		No	Neither
101	17/EE/0291	203703	Phase III trial-pembrolizumab or brentuximab vedotin-Hodgkin Lymphoma	15/06/2017	03/08/2017			13/12/2017		14/12/2017		No	Sponsor
102	17/EE/0303	228718	Effect of MIN-102 in Male Patients with Adrenomyeloneuropathy	23/06/2017	03/10/2017							No	Neither

103	17/LO/0693	226490	Long-term safety of Everolimus in patients with TSC related seizures	27/06/2017	19/09/2017			25/09/2017		27/09/2017		no	Neither
104	14/LO/0187	143913	TAS-120	10/07/2017	04/07/2017			13/10/2017		06/11/2017		No	Sponsor
105	17/LO/0506	220370	AMELIA	10/07/2017	12/07/2017	05/07/2017	20/09/2017		26/09/2017			No	Neither
106	17/NS/0065	219548	Physical Activity and Stoma Study	12/07/2017	31/10/2017					28/11/2017		Within 70 days	
107	17/LO/1656	229212	CO39722 IMspire 170	13/07/2017	09/10/2017	14/11/2017						No	Neither

108	16/EM/0181	201126	TAMARIN	12/07/2017	26/10/2017							Within 70 days	
109	17/ES/0107	231506	Single arm study of Safety and Efficacy of Coversin in adult aHUS	20/07/2017	26/09/2017	14/09/2017						No	Sponsor
110	17/NE/0234	228388	MK3475-629	24/07/2017	08/11/2017			17/11/2017		20/11/2017		Within 70 days	
111	17/EE/0376	232157	Anetumab ravtansine thorough ECG and drug interaction study with CYP3A4	31/07/2017	06/11/2017							Within 70 days	
112	17/LO/1306	228268	REACH 3	27/07/2017	18/08/2017							No	Sponsor
113	17/ES/0040	223878	IMvigor 130	07/08/2017	18/08/2017			19/10/2017		09/11/2017		No	Neither
114	17/NS/0077	218279	BLAST OSA study version 01	09/08/2017	01/11/2017			17/11/2017		07/12/2017		Within 70 days	

115	17/EE/0370	233951	TNT009-01: SAFETY, TOLERABILITY AND ACTIVITY OF TNT009	23/08/2015	17/11/2017							Within 70 days	
116	16/LO/0994	204296	Study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783	25/08/2017	19/09/2017							No	Sponsor
117	17/EE/0368	213669	STRESS-L	01/09/2017	19/12/2017							Within 70 days	
118	17/EE/0040	222216	ENCIRCLE Trial	11/09/2017	27/10/2017							Within 70 days	
119	17/LO/1502	232726	ISIS-443139-CS2 - Open label extension study	12/09/2017	09/11/2017	09/11/2017			23/11/2017			Within 70 days	

120	15/LO/1326	148997	GON migraine study	20/09/2017	06/12/2017							Within 70 days	
121	17/SW/0247	231651	NP39403-RO6870810 as monotherapy and in combination in advanced MM	21/09/2017	20/10/2017							No	Sponsor
122	17/LO/1896	233209	A Phase 1 study of ADCT-502 in patients with advanced solid tumours	22/09/2017	06/11/2017	24/10/2017						Within 70 days	
123	17/LO/1140	223446	K0-TIP-001	03/10/2017	25/10/2017							Within 70 days	

124	17/NS/0018	223787	FUTURE Study	13/10/2017	17/11/2017	11/08/2017						Within 70 days	
125	17/LO/1900	235038	INCB 01158-203	23/10/2017	21/11/2017	21/12/2017						Within 70 days	
126	16/LO/1637	211258	First-in-human, trial of HuMax-AXL-ADC in patients with solid tumours	25/10/2017	07/11/2017							Within 70 days	
127	17/LO/1920	235022	Cardinal (BIVV009-03)	31/10/2017	08/12/2017							Within 70 days	
128	17/LO/1921	236323	Cadenza (BIVV009-04)	31/10/2017	08/12/2017							Within 70 days	
129	17/SC/0229	225742	OCTIMET OMO1	01/11/2017	07/11/2017							Within 70 days	
130	17/WS/0256	233393	BLU-667-1101	01/11/2017	30/11/2017							Within 70 days	
131	17/LO/2060	230779	ZUMA-7	02/11/2017	18/12/2017							Within 70 days	
132	14/EE/1045	139349	POSEIDON trial CRF	21/11/2017	31/10/2017							Within 70 days	
133	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric	24/11/2017	15/12/2017							Within 70 days	

			Transplantation										

Delivering Clinical Research

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	174407	15/LO/0681	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients with Early Manifest Huntington's Disease	Number Agreed	6	6	Date Agreed	Nov-15	6	22/02/2017	6	Recruitment Finished
2	146896	15/LO/0009	A Prospective Development Study evaluating Focal Therapy using Encage™ Coiled Bipolar Radiofrequency Ablation in Men with Localised Prostate Cancer	Number Agreed	20	20	No Date Agreed by Sponsor		23	28/02/2017	23	Recruitment Finished
3	187068	15/LO/1500	Investigation of drug-drug interaction between nintedanib and pirfenidone in patients with IPF (an open label, multiple-dose, two group study)	Number Agreed	2	2	Date Agreed	Jul-16	3	14/03/2017	3	Recruitment Finished
4	17797	14/SC/1340	A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease	Number Agreed	10	10	Date Agreed	27/11/2015	10	05/04/2017	10	Recruitment Finished

5	211983	16/EM/0408	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	3	3	No Date Agreed by Sponsor		8	10/04/2017	8	Recruitment Finished
6	151325	14/SC/1340	A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease	Number Agreed	7	7	Date Agreed	27/11/2015	10	21/04/2017	10	Recruitment Finished
7	15394	13/EM/0373	An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma	Number Agreed	3	3	Date Agreed	01/01/2015	1	25/04/2017	1	Recruitment Finished
8	186018	15/LO/1441	A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura	Number Agreed	18	18	Agreed	Nov-17	18	29/04/2017	18	Recruitment Finished
9	184386	15/EM/0454	An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus	Number Agreed	24	24	Date Agreed	Jun-16	24	04/05/2017	24	Recruitment Finished
10	193988	16/LO/0334	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction	Number Agreed	2	2	Date Agreed	May-17	2	05/05/2017	2	Recruitment Finished

			Adenocarcinoma									
11	187317	16/NE/0027	A phase 3, multicenter, randomized, open-label study of avelumab (MSB0010718C) alone or in combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum resistant/refractory ovarian cancer	Number Agreed	3	3	Date Agreed	Nov-16	23	15/05/2017	23	Recruitment Finished
12	172123	15/LO/0443	A PHASE 3, MULTICENTER,RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA	Number Agreed	6	6	Date Agreed	2017	5	15/05/2017	5	Recruitment Finished
13	158625	14/LO/1597	A Randomized, Double-Blind, Placebo-Controlled, Four-Arm,Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phospha	Number Agreed	5	5	Date Agreed	Jan-16	12	18/05/2017	12	Recruitment Finished
14	195511	15/WM/0457	An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and	Number Agreed	5	5	Date Agreed	Sep-16	7	18/05/2017	7	Recruitment Finished

			an Immunomodulatory Agent									
15	202124	16/LO/1450	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors	Number Agreed	4	4	Date Agreed	30-Jun-18	5	19/05/2017	5	Recruitment Finished
16	182750	15/SW/0220	A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Axial Nonradiographic Spondyloarthritis	Number Agreed	3	3	Date Agreed	17-Jul-17	1	02/07/2017	1	Withdrawn By Sponsor
17	199970	16/SW/0090	Ustekinumab in Subjects with Radiographic Axial Spondyloarthritis	Number Agreed	3	3	Date Agreed	31-Jul-17	1	30/05/2017	1	Withdrawn By Sponsor
18	204761	16/SC/0341	A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function	Number Agreed	3	3	Date Agreed	Oct-17	2	02/06/2017	2	Recruitment Finished
19	201997	16/LO/1612	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)	Number Agreed	20	20	No Date Agreed by Sponsor			09/06/2017	17	Recruitment Finished

20	193141	16/LO/0083	A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus best supportive care versus best supportive care in adults who require regular red-blood cell transfusions due t	Number Agreed	3	3	Date Agreed	Feb-18	5	10/06/2017	5	Recruitment Finished
21	188788	15/LO/1670	Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum-Based Therapy in First Line Setting in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Number Agreed	12	12	Date Agreed	Apr-17	2	21/06/2017	4	Recruitment Finished
22	200426	16/NW/0379	LY2801653 and LY3009806 - Advanced or Metastatic Biliary Tract Cancer	Number Agreed	8	8	Date Agreed	May-17	4	03/07/2017	4	Recruitment Finished
23	194393	16/EE/0011	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Number Agreed	3	3	No Date Agreed by Sponsor			24/07/2017	1	Withdrawn By Sponsor
24	203281	16/EM/0165	A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer (CANC 5545)	Number Agreed	2	2	Date Agreed	22-Mar-18	2	28/07/2017	2	Recruitment Finished
25	166004	14/LO/2156	A Phase 2 Proof of Concept (PoC), DoubleBlind, Randomised, Placebocontrolled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VSN16R for the	Number Agreed	75	75	No Date Agreed by Sponsor		81	31/07/2017	81	Recruitment Finished

			treatment of spasticity in patients with Multiple Sclerosis.									
26	207331	16/EE/0243	A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study Of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects with Unilateral Meniere's Disease	Number Agreed	5	5	Date Agreed	31-Mar-17	1	05/09/2017	1	Withdrawn By Sponsor
27	199027	16/SC/0076	A Pilot Double-blind, Placebo-controlled Crossover Study to Explore the Possible Benefit of AUT00063, an Oral Modulator of Voltage-gated Potassium Channels, in Adult Post-lingual Unilateral Cochlear Implant	Number Agreed	8	8	No Date Agreed by Sponsor		2	27/03/2017	2	Recruitment Finished
28	0	10/H1102/44	MCRN146 (AC-056C501)	No Number Agreed	0	0	No Date Agreed by Sponsor	No Date Agreed by Sponsor		19/10/2017	2	End of Study
29	183134	15/LO/1936	CANC - 4615	Number Agreed	3	3	Date Agreed	31/05/2017		13/11/2017	2	Sponsor has stopped making drug.
30	199690	16/SS/0134	STRO 4724	Number Agreed	1	1	No Date Agreed by Sponsor	No Date Agreed by Sponsor	1	17/11/2017	1	Closed early by sponsor
31	208154	16/EE/0337	Effectiveness and safety of lemborexant in patients with Insomnia	Number Agreed	8	50	No Date Agreed by Sponsor	No Date Agreed by Sponsor	0	27/10/2017	0	End of Study

32	209789	16/LO/1810	UTX-TGR-304	Number Agreed	3	3	Date Agreed	30/05/2018	3	12/10/2017	0	Trial reached global target recruitment early. Originally projected as December 18. Trial only opened in July 17 at UCLH
33	199019	16/LO/1960	Dose finding study of Sarilumab in children with sJIA	Number Agreed	1	1	No Date Agreed by Sponsor	No Date Agreed by Sponsor	No Date Agreed by Sponsor	20/11/2017	0	No patients screened as this study is a rare disease.
34	205613	16/LO/1436	Potential Predictors of Disease Progression in aHUS Patients	Number Agreed	10	10	Date Agreed	30/06/2018	Study closed before agreed date	31/10/2017	6	Sponsor Decision
35	222705	17/EM/0089	BREAKOUT	Number Agreed	10	10	Date Agreed	28/02/2018	Early termination of study –	15/11/2017	1	Early termination of study – sponsor decision